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Preliminary evidence on the uptake, use and 
benefits of the CONSORT-PRO extension 
Abstract  
Purpose 
This study assessed the uptake of the CONsolidated Standards of Reporting Trials (CONSORT) - 
Patient-Reported Outcomes (PRO) statement; determined if use of CONSORT-PRO was associated 
with more complete reporting of PRO endpoints in randomised-controlled trials (RCTs); and 
identified the extent to which high-impact journals publishing RCTs with PRO endpoints endorse 
CONSORT-PRO.  
Methods 
CONSORT-PRO citations were identified by systematically searching Medline, EMBASE, and Google 
from 2013 (year CONSORT-PRO released) to 17 December 2015. RCTs that cited CONSORT-PRO 
(cases) were compared to a comparable control sample of RCTs in terms of adherence to CONSORT-
PRO using t-tests. General linear models assessed the relationship between CONSORT-PRO score and 
key, pre-specified variables. 
The 100 highest-impact journals that published RCTs with PRO endpoints (2014-2015) were 
identified via a systematic Medline search. Instructions for authors were reviewed to determine 
whether journals endorsed CONSORT-PRO. 
Results 
Total CONSORT-PRO scores ranged from 47-100% for cases and 25-96% for controls. Cases had 
significantly higher total CONSORT-PRO scores compared to controls: t=2.64, p=0.01. ‘Citing 
CONSORT-PRO’, ‘journal endorsing CONSORT-PRO’ and ‘dedicated PRO paper’ were significant 
predictors of higher CONSORT-PRO adherence score: R2=0.48, p<0.001.  11/100 top-ranked journals 
endorsed CONSORT-PRO in their instructions to authors, seven of these journals published RCTs 
included as cases in this study.  
Conclusion 
This study demonstrated improved PRO reporting associated with journal endorsement and author 
use of the CONSORT-PRO extension. Despite growing awareness, more work is needed to promote 
appropriate use of CONSORT-PRO to improve completeness of reporting; in particular stronger 
journal endorsement of CONSORT-PRO. 
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Complete, transparent reporting of randomised controlled trials (RCTs) is essential if readers are to 
understand study objectives, evaluate methodology and interpret results [1].  Yet many RCTs fail to 
adequately report this information, resulting in significant research waste [2]. The CONsolidated 
Standards Of Reporting Trials (CONSORT) Statement 2010 [3] provides a minimum set of evidence-
based criteria for high-quality reporting of RCTs. The CONSORT Statement has been endorsed by 
over 600 medical journals, by major editorial organisations and has been cited in over 8000 
publications [4]. Trials published in journals that endorse the CONSORT Statement are reported 
more completely than those in non-endorsing journals [5]; and improved reporting of RCTs over 
time in thoracic surgery [6] and traumatic brain injury [7] has been attributed to the use of the 
CONSORT statement. 
Yet the CONSORT Statement does not specifically address the reporting of patient-reported 
outcomes (PROs). High-quality PRO evidence provides the patient’s perspective on the impact of 
disease and treatment on everyday functioning and quality of life [8] and is critical for a patient-
centred approach to clinical care and policy. 
The CONSORT-PRO Extension was released in 2013 in response to a recognised need for specialised, 
expert-endorsed PRO reporting guidance[9]. Prior reviews indicated suboptimal PRO reporting 
[10,11], which limited the potential for PRO evidence to impact practice, thus representing a waste 
of research effort. CONSORT-PRO aims to facilitate translation of high-quality PRO evidence to 
clinical practice and policy [12]. It adds five PRO-specific extension items to the CONSORT-2010 
Statement and provides PRO-specific elaborations to nine CONSORT-2010 items [9].  In this paper, 
the International Society for Quality of Life Research (ISOQOL) Best Practices for PRO Reporting 
Taskforce (hereafter ‘ISOQOL Reporting Taskforce’) sought to: 1) assess the uptake of CONSORT-PRO 
by identifying articles that cited the CONSORT-PRO Extension in the first three years since its release; 
2) identify published RCTs that cited CONSORT-PRO and describe their adherence to the statement; 
3) compare the quality of PRO reporting in RCTs that cited CONSORT–PRO to  a control sample; 4) 
identify predictors of CONSORT-PRO adherence; 5) identify which journals publish RCTs with PRO 
endpoints, so that these journals can be included in future knowledge transfer efforts led by the 
ISOQOL Reporting Taskforce; and 6) describe to what extent journals publishing RCTs with PRO 
endpoints endorse CONSORT-PRO. 
Methods 
Identification of publications citing CONSORT-PRO 
Medline (Web of Science), EMBASE and Google were systematically searched for all articles that 
cited the CONSORT-PRO extension: 27 February 2013 (release date)-17 December 2015. This was 
achieved by identifying the CONSORT-PRO manuscript[9] within each search engine and selecting 
the ‘search citing articles’ option. Search results were coded by two authors (RMB, JR) according to 
publication type, e.g. RCT, systematic reviews, etc.  
Adherence to CONSORT-PRO  
RCTs that reported PRO results and cited CONSORT-PRO were considered “cases”.  A comparable 
control sample of 40 RCTs was identified, frequency-matched[13] to cases on: year of publication, 
disease (oncology/non-oncology), journal impact factor (IF), and PRO endpoint status (primary or 
secondary).These variables were agreed by all authors to potentially influence the quality of PRO 
reporting. Frequency-matching enables a fair comparison by ensuring there is a balanced mix of key 
variables across the sample. This approach was necessary as it was not possible to match cases and 
controls individually on each of the four specified variables. Controls were sourced firstly from 
journals that published cases (n=33 publications, 15 journals) matching on at least one other key 
variable (publication year, disease, PRO endpoint status), and the remaining RCTs (n=7, from 6 
journals) were identified through Medline. The control sample was finalised objectively by the team 
prior to any publications being evaluated, where each was selected to achieve the best possible 
balance at the sample level.  
Review of adherence to CONSORT-PRO items  
Each publication was reviewed against the CONSORT-PRO checklist adapted for review purposes 
(Appendix 1) by two independent authors (among RMB, JR, PH, LM) and discrepancies were 
resolved upon discussion (RMB, JR, MK). We adapted the CONSORT-PRO checklist by excluding item 
4a (whether PROs used in eligibility or stratification) because it was impossible to check if trials used 
such criteria, and hence whether reporting was required, without checking the trial protocols. 
Adherence to this item is described.  Additionally, checklist items that included multiple 
recommendations (e.g. items P2b, P6, 13a, 17a, P20/21) were each divided into separate sub-items 
for the evaluation, as shown in Appendix 1. Item 7a (PRO sample size calculation) is required only for 
RCTs with a primary PRO endpoint, and assessed accordingly. For each checklist item, the maximum 
item score (0.5 or 1) was awarded if the publication reported information required, except for Item 
P1b, where publications were awarded 1 point if the abstract reported the PRO and its status as a 
primary or secondary endpoint, 0.5 points if the PRO was mentioned but its endpoint status was 
unclear, zero points if the PRO was not mentioned in the abstract.  
Comparison of adherence to CONSORT-PRO between cases and controls 
Two adherence scores were calculated for each publication: 1) the five CONSORT-PRO extension 
items alone, giving a score out of 7 (‘Extension adherence’); and 2) the ‘total CONSORT-PRO 
adherence’ (the complete set of CONSORT-PRO items, maximum score: 14 for RCTs with a secondary 
PRO endpoint and 15 for primary PRO endpoints). Scores were converted to a percentage to enable 
pooling of all RCTs for analysis, regardless of PRO endpoint status. We conducted two independent t 
tests, one for each adherence score, to compare mean adherence between cases and controls.  
We also compared each group’s (cases and controls) overall adherence to CONSORT-PRO items and 
graded adherence according to pre-specified thresholds. If more than 80% of RCTs within each group 
addressed the CONSORT-PRO item we interpreted compliance to be “good”, “moderate” if 50-79% 
RCTs addressed the item, and “poor” if ≤49% of RCTs addressed the item.  
Predictors of higher CONSORT-PRO score 
We pooled cases and controls (n=66) to assess predictors of ‘total adherence’ and ‘extension 
adherence’ scores, running separate general linear models for each score. The models included the 
following factors:  journal endorsement of CONSORT-PRO (three levels: CONSORT-PRO endorsed, 
CONSORT or EQUATOR  (Enhancing the QUAlity and Transparency Of health Research)[14] endorsed 
only, No guidelines endorsed); PRO endpoint status (primary/secondary); whether a CONSORT-PRO 
author was involved in the RCT (Y/N); whether CONSORT-PRO was cited (Y/N) and whether the PRO 
was reported in a dedicated paper (Y/N); and journal IF as a covariate, using backwards deletion. 
These covariates were pre-specified by Taskforce members as potentially affecting CONSORT-PRO 
adherence. We intentionally limited the number of covariates in our model to one predictor per 10 
cases to avoid over-fitting [15]. We did not include year of publication in the model due to limited 
range (2013-2015), but examined this separately using Pearson correlation (α=0.05). All analyses 
were conducted using IBM SPSS Statistics 24. 
Identification of high-impact journals publishing RCTs with PRO endpoints 
We identified a list of highest impact journals publishing RCTs with PRO endpoints by searching 45 
relevant Thomson Reuters journal subject categories [16] (Appendix 2), which were independently 
selected and agreed-on by three authors (JR, MP, MB). Journals were ranked by IF (highest to 
lowest). We then searched Medline using: 1) journal title (working down the list); 2) year (2014-
2015); and 3) “Quality of life” OR “patient reported outcome*” AND “randomized controlled trial”; 
until we had identified the 100 top-ranked journals that published at least one RCT with a PRO 
endpoint during 2014-2015.  
Journals endorsing CONSORT-PRO 
The “Instructions to Authors”  of each of these journals’ websites were screened to determine 
whether they recommended compliance with EQUATOR, CONSORT and/or CONSORT-PRO 
guidelines, the strength of these recommendations and whether authors were required to submit 
CONSORT checklists or flow diagrams, by two authors (JR, MP) and discrepancies were settled with a 
third author (MB). Recommendations were coded on a study-specific ordinal-scale, as follows: 1) 
“mandatory:” defined as use of strong language in relation to reporting guidance, e.g. "must 
conform", "mandatory", "required"; 2)“strongly recommended:” journals that recommended use of 
guidelines without mandating them, and used less binding language, e.g. “please send”, “should 
submit”; and 3)“suggested:” journals that simply suggested use of reporting guidelines, e.g. “we 
encourage you”, “will not insist on”, “may provide” or 4) “mentioned without recommendation:” if 
guidelines were cited in author instructions but no specific recommendations were made, e.g. “to 
find reporting guidelines, visit…”; or  5) “No mention:” when no recommendations or reference to 
reporting guidelines were provided. 
Results 
Publications citing CONSORT-PRO 
We identified 214 unique articles that cited CONSORT-PRO (Figure 1); 27 (13%) articles in 2013, 90 
(42%) in 2014, 94 (44%) for 2015 (at 17 December) and a further 3 (1%) dated ahead of print to 
2016. The journals citing CONSORT-PRO most often were Health and Quality of Life Outcomes, 
Journal of Clinical Oncology, PLOS One and Quality of Life Research, each with 6 (3%) citing articles; 
Cancer (n=5, 2%); and Journal of Clinical Epidemiology (n=4, 2%). 
Twenty-eight (13%) of the citing articles were RCTs, two of which were excluded from further 
analysis as they cited CONSORT-PRO incorrectly (i.e. the RCT did not include a PRO endpoint and 
should rather have cited CONSORT-2010 (Figure 1)). Remaining citations were from opinion or 
discussion papers (n=69, 32%), systematic reviews (n=40, 25%), other original research reports 
(n=20, 9%), guidelines/development of guidelines (n=13, 6%), methodological studies (n=14, 7%), 
non-patient studies (n=8, 4%), non-English original research (n=5, 2%), research protocols (n=2, 1%) 
and conference presentations (n=2, 1%). Of the 26 RCTs, the majority were oncology trials (n=10, 
39%), fibromyalgia (n=3, 11%), haematology (n=2, 8%), genetic counselling (n=2, 8%) and weight 
management (n=2, 8%).  44/214 citing articles (including 3 RCTs) had a co-author who was involved 
in the development of CONSORT-PRO[12,9] or its predecessor, the ISOQOL PRO reporting standards 
[17]. 
RCT adherence to CONSORT-PRO: comparison of cases to controls  
Overall adherence to CONSORT-PRO 
Characteristics of RCT “cases” (RCTs that cited CONSORT-PRO) and “controls” are presented in Table 
1, and RCTs are listed in Appendix 3. The 26 cases had significantly higher total CONSORT-PRO 
adherence scores (mean 77.7% of items, range: 46.7-100%), compared to controls (mean 67.6%, 
range: 25.0-96.4%), t=2.64, p=0.01.  
For the extension adherence score, a larger difference was found between cases (mean 77.5%, range 
28.6-100%) and controls (mean 59.5%, range 21.4-92.9%), t=4.50, p<0.001.  
Item-level comparisons are presented in Table 2. Cases and controls had good overall compliance to 
Items 2a (Rationale for PRO endpoint) and Item 17ai (reporting results of appropriate PRO domains); 
and both groups had poor compliance for Items P1b (PRO identified as RCT endpoint in abstract), 
and P6aiii (mode of questionnaire administration). Overall, cases had good compliance for a higher 
proportion of items (53% compared to 26% for controls), and a lower proportion of items with poor 
compliance (11% compared to 32% for controls).  
Regarding item 4a, which was excluded from our scoring, none of the included RCTs described using 
PROs in stratification procedures, however 10 (15%) reported PRO-specific eligibility criteria, 
including inclusion of participant reaching a threshold PRO score (n=4, 6%) RCTs, ability to complete 
questionnaires (n=3, 5%), timely submission of baseline questionnaire (n=2, 3%). A further 9 (14%) 
RCTs described PRO-relevant eligibility criteria, including language proficiency (n=7, 11%) and ability 
to comply with trial procedures (n=2, 3%). Of these 19 RCTs reporting PRO-specific or relevant 
eligibility criteria, 6 (21%) were cases and 12 (63%) had a primary PRO endpoint. 
Predictors of higher CONSORT-PRO score 
There were three significant predictors of higher CONSORT-PRO total adherence score: ‘citing 
CONSORT-PRO’, ‘journal endorsing CONSORT-PRO’ and ‘dedicated PRO paper’ (R2=0.48, p<0.001). In 
the model for the 5 extension items only, there were two significant predictors: ‘citing CONSORT-
PRO’, ‘journal endorsing CONSORT-PRO’(R2=0.36, p<0.001). 
We did not observe a relationship between year of publication and CONSORT-PRO total adherence 
score (r=0.11, p=0.39) or Extension adherence score (r=0.05, p=0.68). 
Journals publishing RCTs with PRO endpoints 
The journal subject categories search resulted in a list of 2,976 journals. The target of identifying the 
100 top-ranked journals publishing RCTs with PRO endpoints was reached after reviewing 324 
journals (IF range 55.873 to 4.613, Appendix ). The 100 top journals published 397 RCTs with PRO 
endpoints during 2014 and 2015 (Table 3). Most of these RCTs were published in oncology (n=98 
RCTs, 25%) and in general and internal medicine journals (n=52 RCTs, 13%).   
Of the 26 RCTs (19 journals) included as cases in this study, 13 RCTs (50%) were published in seven 
journals on this top-100 list, namely: Health Technology Assessment, Journal of Clinical Oncology, the 
European Journal of Cancer, European Urology, Lancet Neurology, Lancet Oncology, Pain.  
Journals endorsing CONSORT-PRO and strength of guideline 
recommendations  
Of the 100 top-ranked journals that published a RCT with a PRO endpoint, 80 mentioned CONSORT 
in their instructions to authors and 11 mentioned CONSORT-PRO (Table 4; shaded grey). For 38 
journals, it was mandatory for authors to adhere to the CONSORT guidelines. In contrast, no journals 
deemed it mandatory for authors to use CONSORT-PRO guidelines. A total of 14 journals requested a 
CONSORT checklist be completed, eight requested a CONSORT flowchart, and 38 requested both. 
Seven of the 100 highest-impact journals published 13 (50%) of the 26 RCT cases in this study, and all 
seven journals strongly or moderately endorsed the CONSORT Statement; 4/7 (57%) cited the 
EQUATOR Network (without making a strong recommendation for using EQUATOR guidelines); and 
2/7 (29%) endorsed CONSORT-PRO. 
Of all 66 RCTs included in this study as cases or controls, 15 RCTs (23%) were published in two 
journals that specifically endorsed CONSORT-PRO (Namely Journal of Clinical Oncology and PLOS 
One) and 37 (56%) RCTs (published in 14 journals) endorsed use of CONSORT-2010 or the EQUATOR 
guidelines without specifically endorsing CONSORT-PRO. The remaining journals failed to endorse 
any reporting guidelines. 
Discussion 
This is the first study to describe the uptake of the CONSORT-PRO extension, and its association with 
the completeness of PRO reporting. CONSORT-PRO has been highly cited since its publication, 
although many of these citations are in review articles and discussion papers written by PRO experts 
rather than clinical trials experts. This has served the purpose of disseminating the guidance within 
relevant research contexts. The increasing number of RCTs citing CONSORT-PRO is encouraging. It 
suggests increased understanding of the need for complete and transparent PRO reporting for clear 
communication of research findings, the value of high-quality PRO data generally, and growing 
awareness of CONSORT-PRO.  
Only 26 RCTs appropriately cited CONSORT-PRO during the study period, which represents a minute 
proportion of RCTs reporting PRO results overall in that period, given 26,337 RCTs with PRO 
endpoints were registered between 2007-2013 [18], and that we identified 397 RCTs including PROs 
published 2014-2015 in the 100 top-ranked PRO RCT journals alone.  
We acknowledge that failure to cite CONSORT-PRO does not imply failure to use CONSORT-PRO; we 
merely use this metric to estimate the extent of awareness. We acknowledge potential barriers to 
citing CONSORT-PRO; for example some journals restrict the number of publication references and 
there is no obligation for authors who use CONSORT-PRO to cite it. Nonetheless, we suspect the 
main barrier to use of CONSORT-PRO is a widespread lack of awareness of its existence and/or 
importance.  
Our finding that citing CONSORT-PRO was related to higher total CONSORT-PRO scores suggests that 
use of CONSORT-PRO facilitates more complete and transparent reporting. We observed an even 
larger difference between cases and controls for the extension adherence score. One possible 
explanation is that control RCTs used CONSORT-2010 to prepare their publications (nine CONSORT-
PRO items are adapted from general items of CONSORT-2010). Alternatively, some of the 26 RCTs 
cases may not have used the full CONSORT-PRO checklist; rather only the five extension items, in 
preparing their manuscripts. If the latter is the case, this is a knowledge transfer concern requiring 
attention, as reporting the five extension items alone will omit key information and limit the 
potential for PRO results to impact clinical practice. For example, the need to report baseline PRO 
results and the number of participants included in PRO analyses are adapted from CONSORT-2010. 
There was also a large range in the CONSORT-PRO adherence scores of cases, revealing that 
awareness of CONSORT-PRO does not guarantee complete reporting. Many RCT abstracts 
mentioned the PRO but failed to indicate whether it was a primary or secondary endpoint. Again, 
these are knowledge transfer concerns requiring intervention to improve reporting practices and to 
ensure PRO results are interpreted accurately so they can appropriately inform patient care.  
Recent reviews confirm that reporting of PRO endpoints remains unsatisfactory overall; particularly 
regarding the reporting of PRO hypotheses, methodology, missing data, and generalisability of 
results [19-26]. Failing to report this information is wasteful as it limits the potential for readers to 
appraise the effect of interventions on patient health status, and the potential for PRO systematic 
reviews to impact clinical recommendations and health policy [27,28]. It may also decrease 
clinicians’ confidence in the value of PRO data [29]. These aforementioned reviews [19-24] 
predominately include RCTs published before CONSORT-PRO. We expect that adherence to 
CONSORT-PRO will improve with time, as awareness and uptake increases. We observed an upward 
trend in the number of CONSORT-PRO citations annually; from 27 in 2013 to 94 in 2015. 
Our review highlighted that most high-impact journals publishing PRO RCTs do not yet recommend 
use of CONSORT-PRO. In fact, many failed to recommend any EQUATOR guidelines. Journal 
endorsement of reporting guidance was a significant predictor of higher CONSORT-PRO adherence 
scores in this study. Half the RCTs that cited CONSORT-PRO appeared in a top-ranked journal, all of 
which journals (n=7) recommended at least one of these reporting guidelines in their instructions to 
authors.  
Therefore, the ISOQOL Reporting Taskforce urges journals to endorse EQUATOR guidelines, including 
CONSORT-PRO, particularly those that publish RCTs with PROs. Many journals already require 
submission of a CONSORT checklist and participant flow diagram, which may explain improvements 
in RCT reporting generally when assessed against CONSORT 2010 [6,7,5], lending further credibility 
to our argument that greater journal endorsement of CONSORT-PRO will improve the standard of 
PRO reporting. The fact that we obtained controls (i.e. articles that reported PRO RCTs but did not 
cite CONSORT-PRO) from journals that endorsed CONSORT-PRO (albeit not strongly) potentially 
indicates that the strength of the recommendation may be an important factor in determining 
adherence to reporting guidelines. 
Similar to past reviews [19,21,23], we found that reporting of PRO endpoints in a dedicated 
publication was a predictor of more complete reporting. Whilst detailed secondary PRO publications 
should be encouraged as they allow for presentation of additional analyses, the principal PRO 
findings should be reported in accordance with CONSORT-PRO and in the main RCT publication to 
facilitate interpretation of PRO results within the context of other endpoints, and to provide the 
patients’ perspective to complement other trial information. This is particularly important to ensure 
PRO research efforts are not wasted. 
Strengths 
This is a comprehensive analysis of the uptake and impact of CONSORT-PRO using mixed methods. 
Publications that evidently used CONSORT-PRO were reviewed against comparable controls. All RCT 
publications and journal instructions to authors were independently reviewed by at least two 
authors using objective criteria.   
Limitations 
We attempted to choose controls from the same journals as the case RCTs, to ensure controls were 
of a comparable quality to cases. However this may have come at a cost to the representativeness in 
terms of overall standard of PRO reporting, particularly given that many of these journals endorsed 
some key reporting guidelines. It is possible that our control sample represents a higher-than-
average picture of the overall standard of PRO-reporting, and that in reality, the difference in 
reporting standards of RCTs that do not use CONSORT-PRO guidance compared to those that do is 
likely to be much larger. Similarity of journals between groups may explain why we did not observe a 
relationship between journal IF and CONSORT-PRO adherence scores.  We excluded the item on PRO 
eligibility or stratification criteria because we could not check trial protocols to determine whether 
this item should be reported, however we observed that a higher proportion of trials in the control 
sample reported PRO-specific or relevant criteria. Our approach of excluding this item from scoring 
has assumed that trials only reported this item if relevant to their trial. We do not believe that 
inclusion of this item in our adherence scoring would have impacted our results. Our review focuses 
on the first three years since CONSORT-PRO was published. It may be too early to observe the 
benefits of CONSORT-PRO guidance; these may become more evident over time as awareness and 
uptake increases. A similar review to ours should be undertaken in future.  
Not all journals are listed in Thomson Reuter ratings and sorting methods other than by highest IF 
could have been used, e.g. by number of RCTs published. We focussed our study on RCT publications 
and journals, however other important stakeholders, such as funding bodies and professional 
research and clinical societies, also play an important role in the promotion of CONSORT-PRO [12]. 
Some notable examples of research organisations already promoting CONSORT-PRO include the 
EQUATOR network [14], CONSORT [30] and UK NIHR Research Design Service Resource[31] websites, 
which include direct  links to CONSORT-PRO. Future research should review the extent to which key 
research and professional organisations, as well as the largest health research funding organisations, 
endorse CONSORT-PRO. 
Conclusions 
Reporting of PROs was more complete in RCT publications that cited CONSORT-PRO than in control 
publications. Additionally, reporting of the PRO endpoint in a dedicated publication, journal 
endorsement of CONSORT-PRO, and citing CONSORT-PRO were significant predictors of higher total 
CONSORT-PRO adherence scores. Many key journals do not endorse CONSORT-PRO in their 
instructions to authors. Although this should not stop authors from using CONSORT-PRO, journals 
are ideally placed to show leadership in recommending reporting guidance to facilitate scientifically 
robust reporting and to ultimately reduce research waste. The ISOQOL Reporting Taskforce 
endeavours to continue educating researchers on the importance of complete PRO reporting by 
disseminating and promoting CONSORT-PRO through health research journals, professional and 
research organisations and funding bodies. 
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Table 1. Characteristics of eligible publications of randomised controlled trials (RCTs) with patient-
reported outcome (PRO) endpoints which cited CONSORT-PRO, i.e. ‘cases’, and frequency-matched 
‘control’ publications (RCTs with PRO endpoints which did not cite CONSORT-PRO. 
 CASES   CONTROLS    
Variable N=26 % N=40 % P value 
PRO Endpoint status        .90 
Primary 10 38% 16 40%  
Secondary 16 62% 24 60%  
Year published         .75 
2012 0 0% 1 3%  
2013 1 4% 2 5%  
2014 12 46% 14 35%  
2015 13 50% 22 55%  
2016 0 0% 1 3%  
Average year 2014.5   2014.5   .83 
           
Disease         .74 
Oncology 10 38% 17 43%  
non-oncology 16 62% 23 58%  
Journal impact factor (IF)          
IF average 8.707   8.753   .84 
IF range limits 1.525 - 24.725  2.125 - 24.725   
*p values demonstrate no significant differences between cases and controls for each variable 
(means or proportions). 
  
Table 2. Adherence frequencies of case papers and control papers to the 14 CONSORT-PRO 
Extension Items 
 
Case RCT papers addressing the 
item (N=26) 
Control RCT papers addressing the 
item (N=40) 
CONSORT-PRO item n  % 
Compliance 
rating n  % 
Compliance 
rating 
P1b. Abstract – PRO as primary/secondary endpoint        
Item P1b completely addressed 10 38 Poor 25 38 Poor 
Item P1b partially addressed 15 58 Moderate 14 21 Poor 
2a. Rationale for including PRO endpoint 22 85 Good 37 93 Good 
P2bi. PRO hypothesis present 19 73 Moderate 9 23 Poor 
P2bii.PRO domains in hypothesis 13 50 Moderate 6 15 Poor 
P6ai. Evidence of PRO instrument validity  
24 92 Good  29 73 Moderate 
P6aii. Statement of the person completing the PRO50 questionnaire 
21 81 Good 31 78 Moderate 
P6aiii. Mode of administration (paper, e-PRO) 
9 35 Poor 10 25 Poor 
P7a.How sample size was determined (not required unless PRO is a 
primary endpoint) 
6* 67* Moderate 10 63 Moderate 
P12a. Statistical approach for dealing with missing data (imputation, 
exclusion, other) 
20 77 Moderate 20 50 Moderate 
13ai. Report no. questionnaires  submitted/available for analysis at 
baseline 
19 73 Moderate 26 68 Moderate 
13aii. Report no. questionnaires  submitted/available for analysis 
principle time point for analysis  
21 81 Good 27 73 Moderate 
15. Demographics table includes baseline PRO 19 73 Moderate 34 85 Good 
16. Number of pts (denominator) included in each PRO analysis   
21 81 Good 29 73 Moderate 
17ai. PRO results reported for the hypothesised domains and time 
point specified in the hypothesis –OR- reported for each domain of 
the PRO questionnaire if no PRO hypothesis provided 
24 92 Good 34 85 Good 
17aii. Results include confidence interval, effect size or some other 
estimate of precision 
21 81 Good 30 75 Moderate 
18. Results of any subgroup/adjusted/exploratory analyses  14 54 Moderate 18 45 Poor 
P20. PRO study limitations 20 77 Moderate 30 75 Moderate 
P21. Implications of PRO results for generalizability, clinical practice 
21 81 Good 33 83 Good 
22. PROs interpreted in relation to clinical outcomes  
21 81 Good 34 85 Good 
Totals 
      
CONSORT-PRO items with good compliance 10 50  5 25  
CONSORT-PRO items with moderate compliance 8 40  9 45  
CONSORT-PRO items with poor compliance 2 10  6 30  
Compliance rating cut-off scores: “good” = >80% of RCTs within the group addressed the item; “moderate” = 50-79% of 
RCTs within the group addressed the item; “poor”= ≤49% RCTs within the group addressed the item. *One RCT with a 
primary PRO endpoint was excluded from this count as it was a pilot trial. 
Table 3. Journal subject category and number of RCT-publications with PRO endpoints (“RCT-PRO”) included in 
our review of journal instructions to authors 
Journal Subject Category* No. of included 
journals  
No. of RCT-PRO 
publications 
Total RCT-PRO 
publications 
Cardiac & cardiovascular systems 
    And peripheral vascular disease 
9 
1 
17 
5 
22 
Clinical neurology 
    And peripheral vascular disease 
    And psychiatry and surgery 
    And anesthesiology 
5 
1 
1 
1 
17 
2 
2 
4 
25 
Critical care medicine 
    And respiratory system 
1 
2 
1 
10 
11 
Emergency medicine 1 2 2 
Endocrinology & metabolism 4 12 12 
Gastroenterology & hepatology 
    And pharmacology & pharmacy 
9 
1 
24 
5 
29 
Geriatrics & Gerontology 2 3 3 
Health care sciences & services 1 12 12 
Hematology 
    And peripheral vascular disease 
2 
1 
6 
1 
7 
Immunology 
    And allergy 
    And infectious diseases 
 
3 
1 
 
8 
1 
9 
Medicine, general & internal 
    And primary care 
7 
1 
51 
1 
52 
Nutrition & dietetics 
    And endocrinology & metabolism 
1 
1 
1 
1 
2 
Obstetrics & gynecology 2 6 6 
Oncology 
    And respiratory system 
9 
1 
94 
4 
98 
Ophthalmology 1 6 6 
Pediatrics 1 2 2 
Pharmacology & pharmacy 1 1 1 
Psychiatry 
    And clinical neurology and pharmacology 
    And endocrinology 
    And psychology 
    And substance abuse 
6 
1 
1 
3 
1 
9 
1 
1 
9 
1 
21 
Radiology, nuclear medicine & medical imaging 2 2 2 
Respiratory system 3 21 21 
Rheumatology 3 16 16 
Sport sciences 1 1 1 
Surgery 
    And orthopedics 
3 
1 
21 
2 
23 
Urology & nephrology 4 14 14 
TOTAL 100 397 397 
*as classified in the Thomson Reuters’ 2014 Journal Citation Reports, Science Edition 
  
Table 4. Top 100 journals that published RCTs with PRO endpoints and strength of the journals’ 
recommendations for use of EQUATOR, CONSORT and CONSORT-PRO guidance  
 Examples of qualifying 
language 
EQUATOR* 
n 
CONSORT† 
n 
CONSORT-PRO‡ 
n 
1. Mandatory “Must conform”, 
“mandatory”, “required" 
1 38 0 
2. Strongly recommended “Please send”, “should 
submit” 
2 31 4 
3. Suggested “We encourage you”, “will 
not insist on”, “may provide” 
8 10 1 
4. Mentioned without 
recommendation 
“To find reporting guidelines, 
visit…” 
20 1 6 
5. Not mentioned No mention of reporting 
guidance 
69 20 89 
Total n  100 100 100 
*EQUATOR: Enhancing the QUAlity and Transparency Of health Research; † CONSORT: CONsolidated Standards of Reporting Trials; ‡ 
CONsolidated Standards of Reporting Trials - Patient-Reported Outcomes Extension.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1. CONSORT-PRO review criteria & scoring  
 
P1b.  Abstract – PRO noted as primary/secondary endpoint (1= yes, 0.5= PRO mentioned 
but unclear endpoint status; 0=no) 
2a.   Rationale for including PRO (1= yes, 0=no) 
P2bi.  PRO hypothesis present (0.5= yes, 0=no) 
P2bii. PRO domains specified in hypothesis (0.5= yes, 0=no) 
P6ai.  Evidence of PRO instrument validity provided/cited (1= yes, 0=no) 
P6aii.  Statement of the person completing the PRO (e.g. 'patients completed', or 'self-
report') (0.5= yes, 0=no) 
P6aiii.  Mode of administration specified (paper, e-PRO) (0.5= yes, 0=no) 
7a How sample size was determined. Not required for PRO unless it is a primary study 
outcome (1 = yes, 0 = no, N/A = not applicable because PRO was not a primary trial 
endpoint or the trial was a pilot study) 
P12a.  Statistical approach for dealing with missing data specified (imputation, omission 
of cases with missing data) (1= yes, 0=no) 
13ai.  Report number of questionnaires submitted/available for analysis at baseline 
(0.5= yes, 0=no) 
13aii.  Report number of questionnaires submitted/available for analysis principle 
timepoint for analysis (0.5= yes, 0=no) 
15.   Demographics table includes baseline PRO (1= yes, 0=no) 
16.  Number of patients (denominator) included in each PRO analysis and whether this 
was intention to treat (1= yes, 0=no)  
17ai.  PRO results reported for the hypothesised domains and time point specified in the 
hypothesis –OR- reported for each domain of the PROM if no PRO hypothesis 
provided (0.5= yes, 0=no) 
17aii.  Results include confidence intervals, effect size or some other estimate of 
precision (0.5= yes, 0=no) 
18.   Results of any subgroup/adjusted/exploratory analyses are reported (1=yes, 0=no) 
P20.  PRO study limitations provided (1=yes, 0=no) 
P21.  Implications of PRO results for generalizability, use in clinical practice (1=yes, 0=no) 
22.   PROs interpreted in relation to clinical outcomes (1=yes, 0=no) 
 
TOTAL CONSORT-PRO SCORE, Max =15 (primary PRO endpoint) or 14 (secondary PRO 
endpoint) 
Note: All items above are from the original CONSORT-PRO manuscript (Calvert et al, JAMA 2013; 309(8):814-22). This includes  items 
adapted from the CONSORT-2010 adapted for PROs (items NOT prefixed with ‘P’) and 5 new, PRO-specific items (prefixed with ‘P’).  
CONSORT-PRO items that included multiple recommendations (e.g. items P2b, P6, 13a, 17a, P20/21) were each divided into separate 
sub-items for the evaluation, as shown above. 
Figure 1: PRISMA flow diagram: identification of RCTs citing the CONSORT-
PRO Extension 
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 Citing articles identified 
through Google 
(n = 209) 
 
Non-RCTs excluded (n = 
186) 
 
Protocol (n=2); 
Other original research, incl. 5 
non-English studies (n=25); 
Non-patient original research 
(n=8); 
Development of other 
guidelines (n=13); 
Opinion paper/comment (n=69); 
Systematic review (n=54); 
Methodological study (n=14) 
Conference presentation (n=2). 
Full-text RCT articles assessed for eligibility 
for analysis of adherence to CONSORT-PRO 
(n = 28) 
Citing RCTs included in review as “cases” 
(n = 26) 
Duplicates removed 
(n = 136) 
Citing articles identified 
through EMBASE 
(n = 0) 
 
Full-text articles excluded 
(N=2): 
 
No PRO endpoint, i.e. CONSORT-
PRO inco rectly cited  
Titles and abstracts screened for eligibility 
for analysis of adherence to CONSORT-PRO 
(n = 214) 
Note: all 214 publications are included in 
descriptive review of publication types. 
 
